News

Filter

Current filters:

Caprelsa

FDA approves Exelixis' Cometriq for rare thyroid cancer, as EMA accepts filing

30-11-2012

There were two items of good news yesterday for US drug developer Exelixis' (Nasdaq: EXEL), the first…

AstraZenecaBiotechnologycabozantinibCaprelsaCometriqEuropeExelixisNorth AmericaOncologyPharmaceuticalRegulation

Germany's IQWiG finds no proof of added benefit for AstraZeneca's Caprelsa in thyroid cancer

05-07-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit…

AstraZenecaCaprelsaEuropeOncologyPharmaceuticalPricingRegulation

EU approval for AstraZeneca thyroid cancer drug Caprelsa

21-02-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced this morning that the European Commission has…

AstraZenecaCaprelsaEuropeOncologyPharmaceuticalRare diseasesRegulation

AstraZeneca’s thyroid cancer drug Caprelsa gets positive CHMP opinion

18-11-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that its Marketing Authorization…

AstraZenecaCaprelsaEuropeOncologyPharmaceuticalRegulationvandetanib

COMPANY SPOTLIGHT

Menarini

Back to top